Tissue Regenix Group

Tissue Regenix reports its unaudited interim results for the six months ended 30 June 2024 delivering continued progress across many areas of the business and marking the Group's eighth consecutive reporting period of growth. Highlights 📈 Group revenues increased by 16% to USD16.4 million 💵 Adjusted EBITDA* profit more than doubled to USD1.1 million 🌟 Profit before taxation of USD0.1 million & gross profit increased to 53% 💰 Cash position of USD3.5 million  ⬆️ A 29% year-on-year increase in tissue processing throughout H1 2024 🏢 Acquired the building in San Antonio that the Company has occupied since 2021 as part of the Phase 1 and 2 expansion plan Jonathan Glenn, Chair of Tissue Regenix Group plc, said: "It has been another impressive half for the Group and I am pleased to report continued success through the execution of the Group's 4S strategy. The management team has done a stellar job of driving the business forward through headwinds in certain segments and continues to identify expansion opportunities geographically as well as through new surgical indications. During H1 2024, there has been continued growth across all business segments and an improvement in profitability from H1 2023. We retain a strong cash position to see us through our current business plans, including the Phase 2 capacity expansion of the Group's facility in San Antonio, which is expected to complete in 2025." Read the full announcement HERE: https://lnkd.in/eSvYXnSB

Tissue Regenix CEO, Daniel Lee and CFO, David Cocke, will be presenting to investors today with an update on the Company's interim results for the six months ended 30 June 2024. The presentation is open to all potential and existing investors and will take place live at 4.30pm (BST). A recording of the presentation will be available shortly after the meeting has concluded. Register for the meeting here: https://lnkd.in/dpWtxJf

Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke take Proactive's Stephen Gunnion through company’s significant financial progress and strategic growth pillars. Cocke highlighted a strong first half of 2024, with revenues increasing by 16% to $16.4 million. This marks the eighth consecutive growth period, with the gross profit margin rising to 53%, and EBITDA more than doubling to $1.1 million. Notably, the company achieved its first pre-tax profit, a milestone in its history. Discussing the growth drivers, Cocke emphasised the 26% growth in mineralised bone matrix products and the addition of 24 new distributors. The company’s tissue partnerships and regulatory evolution, such as its move to develop medical devices, were key components of the strategy. Watch at #Proactive #ProactiveInvestors http://ow.ly/1KhQ105IcUO

Tissue Regenix CEO, Daniel Lee and CFO, David Cocke, will be hosting a live online presentation relating to the Company's interim results for the six months ended 30 June 2024 on Tuesday 10 September at 4.30pm (BST). Investors can sign up to Investor Meet Company for free and register for the presentation here: https://lnkd.in/dpWtxJf #TRX

 📚 This week’s case study is from Adrienne Denman MD, Board Certified, American Board of Surgeons. 🗣 Dr. Floyd Denman offered her perspective on the use of DermaPure in this pilonidal cyst case: “Pilonidal cyst excisions leave difficult surgical wounds that can be complicated by post-operative wound infection and dehiscence. DermaPure® provides a great matrix for these wounds and aids in the healing process." 🔗 To learn more about DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. *The case study contains some graphic content* #regenerativemedicine #decellularisation #dCELL #TRX #Casestudy #DermaPure

📚 This week’s case study is from Brian Smith DMD, MD Board Certified, American Board of Oral and Maxillofacial Surgery (https://lnkd.in/gdsrzSQD). 🗣 Dr. Smith offered his perspective on the use of DermaPure® in this oromaxillofacial case: “With the total loss of sinus mucosa and structural integrity of the maxilla, there was a high risk of surgical site dehiscence and oral-antral fistula. The use of the internal membrane closure with DermaPure® avoided wound dehiscence, promoted healing, and helped maintain structural integrity of the maxillary nasal complex.” 🔗 To learn more about DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. *The case study contains some graphic content* #regenerativemedicine #decellularisation #dCELL #TRX #Casestudy #DermaPure

📚 This week’s case study is from Mark Ciaglia, DO Board Certified, American Osteopathic Board of Surgeons. Dr. Ciaglia is a hand surgeon in Houston, TX (www.wcfspecialsurgery.com). 🗣 Dr. Ciaglia offered his perspective on the use of DermaPure® in this orthopedic case: “I was concerned about creating a watertight repair, as the tissues were severely attenuated, and the patient already had a communication from the joint. It literally looked like a bomb went off at his common extensor origin. Using the known tissue integration properties of DermaPure®, I confidently repaired the tissues without the worry of a recurrent joint failure.” 🔗 To learn more about DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. *The case study contains some graphic content* #regenerativemedicine #decellularisation #dCELL #TRX #Casestudy #DermaPure

Tissue Regenix provides an unaudited trading update for the six months ended 30 June 2024.   Highlights ✅ Group revenues ~$16.4 million (H1 2023: $14.1m), 16% increase y-o-y & record first half 📈 Seventh consecutive reporting period of growth ⬆️ Expected growth in adjusted EBITDA for H1 2024 💵 Cash position remains sufficient to support the current business expansion plans   Daniel Lee, CEO commented: "After delivering maiden profitability with our FY 2023 numbers, it is particularly pleasing to announce another period of progress, not only financially but also operationally. Our 4S strategy continues to deliver benefits, and our tactical growth pillars should drive further growth and deliver the results that are expected by our stakeholders. We are firmly committed and confident in keeping Tissue Regenix on its positive trajectory, which began in 2021."   Notice of Results The Group will publish its interim results on Tuesday, 10 September 2024.   Read the full announcement here: https://lnkd.in/dgYUNeC

 📚 This week’s case study is from Adrienne Denman MD, Board Certified, American Board of Surgeons. 🗣 Dr. Floyd Denman offered her perspective on the use of DermaPure in this pilonidal cyst case: “Pilonidal cyst excisions leave difficult surgical wounds that can be complicated by post-operative wound infection and dehiscence. DermaPure® provides a great matrix for these wounds and aids in the healing process." 🔗 To learn more about DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc. *The case study contains some graphic content* #regenerativemedicine #decellularisation #dCELL #TRX #Casestudy #DermaPure

📄 This week’s case study is from Jon Minter, DO Board Certified, American Osteopathic Board of Orthopedic Surgeons. 🗣 Dr. Jon Minter offered this perspective on the use of of ConCelltrate® in this orthopedic case:“ I found #ConCelltrate® 100 to have exceptional handling characteristics and found it to be quite durable as well.” 🔗 If you would like to know more about DermaPure and other company products, please visit the website: https://lnkd.in/exgd3kc #regenerativemedicine #decellularisation #dCELL #TRX #Casestudy #Osteopathic #DermaPure #innovative